19:55 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart failure. In a rat cardiomyoblast cell line, primary rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
07:00 , Jul 14, 2016 |  BC Innovations  |  Translation in Brief

Encouraging self-control

A San Francisco team has addressed the problem of HIV reservoirs by adding a new component - boosting innate immunity - to the "shock and kill" strategy for rooting out the last traces of the...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DEAD box polypeptide 58 (DDX58; RIG-I); histone deacetylase (HDAC)

Infectious disease INDICATION: HIV/AIDS In vitro studies suggest the DDX58 agonist Soriatane acitretin could help treat HIV. In T cells from healthy volunteers infected ex vivo with HIV, Soriatane decreased levels of viral DNA 72...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Dyslipidemia Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with Type I diabetes. A rat model of Type I diabetes had higher GHRH receptor levels in the small intestine...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest GHRH receptor agonists could improve engraftment of islet cell transplant to treat diabetes. In a rat pancreatic β cell line, the GHRH receptor agonist MR-409...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

Myo my

Phase II readouts showing that omecamtiv mecarbil improves cardiac output and physiology could translate into better outcomes and quality of life for chronic heart failure patients, if Amgen Inc. and Cytokinetics Inc. decide to move...
07:00 , Sep 8, 2014 |  BioCentury  |  Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity CD40; tumor necrosis factor receptor-associated factor 6 (TRAF6) Mouse studies suggest inhibiting CD40 signaling through the TRAF6 adaptor...
08:00 , Feb 28, 2013 |  BC Innovations  |  Targets & Mechanisms

Islet transplants find the adrenal gland

German and U.S. researchers have shown that transplantation into the adrenal gland of islet cells preconditioned with an improved peptide agonist of growth hormone-releasing hormone may help normalize glucose levels in diabetic mice better than...